← Back to Screener
FibroBiologics, Inc. Common Stock (FBLG)
Price$1.12
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-98.06%
Price vs S&P 500 (4W)-25.52%
VGM Score16.74
Market Capitalization$6.04M
All Metrics
Book Value / Share (Quarterly)$0.74
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-4.47
Price vs S&P 500 (YTD)-85.16%
EPS (TTM)$-5.21
10-Day Avg Trading Volume0.10M
EPS Excl Extra (TTM)$-5.21
EPS (Annual)$-8.35
ROI (Annual)-302.89%
Cash / Share (Quarterly)$0.42
ROA (Last FY)-193.85%
EBITD / Share (TTM)$-1.42
Cash Flow / Share (Annual)$-5.01
P/B Ratio2.32x
P/B Ratio (Quarterly)2.31x
Net Income / Employee (Annual)$-1,243,100
Net Interest Coverage (TTM)-12.53x
ROA (TTM)-195.56%
EPS Incl Extra (Annual)$-8.35
Current Ratio (Annual)3.61x
Quick Ratio (Quarterly)1.03x
3-Month Avg Trading Volume0.32M
52-Week Price Return-92.27%
Revenue / Employee (TTM)$0
52-Week High$19.80
EPS Excl Extra (Annual)$-8.35
26-Week Price Return-82.13%
Quick Ratio (Annual)2.78x
13-Week Price Return-79.51%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.59x
Enterprise Value$4.81M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.47
3-Month Return Std Dev158.66%
Net Income / Employee (TTM)$-1,245,300
ROE (Last FY)-302.89%
Net Interest Coverage (Annual)-6.62x
EPS Basic Excl Extra (Annual)$-8.35
Total Debt / Equity (Quarterly)0.09x
EPS Incl Extra (TTM)$-5.21
ROI (TTM)-330.24%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-120.47%
Year-to-Date Return-74.22%
5-Day Price Return10.48%
EPS Normalized (Annual)$-8.35
ROA (5Y Avg)-169.07%
Month-to-Date Return-12.12%
EBITD / Share (Annual)$-7.35
EPS Basic Excl Extra (TTM)$-5.21
P/B Ratio (Annual)2.43x
Book Value / Share (Annual)$1.85
Price vs S&P 500 (13W)-89.25%
Beta-0.69x
Revenue / Share (TTM)$0.00
ROE (TTM)-767.07%
52-Week Low$0.95
mGradeF
vgmGradeF
Show chart for
Earnings Surprise History
Q1 26-1.33est. -1.33
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.11
4.11
4.00
4.00
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
FBLGFibroBiologics, Inc. Common Stock | — | — | F | $1.12 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
FibroBiologics Inc is a clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, and psoriasis. The company's pipeline comprises four candidates: CYWC628, CYPS317, CYMS101, and CybroCell, with additional exploration in oncology and age-related conditions, including novel approaches to reverse thymic involution.